Ustekinumab alone for perianal fistulizing crohn's disease
Part of Digestive system clinical trials.
This study looks at how well ustekinumab works on its own for people with perianal fistulizing Crohn's disease, a type of Crohn's that causes painful tunnels near the anus. If you are already taking ustekinumab without other Crohn's medicines, this trial may help show if it can improve your fistulas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have perianal fistulizing Crohn's disease — a type of Crohn's that causes abnormal tunnels (fistulas) near the anus.
- You are currently being treated with ustekinumab (a biologic drug that calms the immune system).
- You are not taking ustekinumab together with steroids, immunosuppressants, other biologics, or small molecule drugs.
- You do not have other autoimmune diseases like lupus, rheumatoid arthritis, or Graves' disease.
- You do not have serious infections (such as active tuberculosis, Epstein-Barr virus, or cytomegalovirus) or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This trial tests a drug called risankizumab (Skyrizi) for people whose Crohn's disease has led to anal fistulas that haven't improved with other treatments. The goal is to see if risankizumab can help these fistulas heal and stop draining.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.